ClinicalTrials.gg
RecruitingNCT06773481Updated Jul 9, 2025

BC008-1A Injection for Recurrent CNS WHO G4 Glioma

A Phase 1 interventional study of BC008-1A and BC008-1A in Glioma, Glioma Tumor Recurrence and Glioma, Recurrent High Grade, sponsored by Sichuan Luzhou Buchang Biopharmaceutical Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-09.

Primary conditionGlioblastomaRegistry: GliomaReclassifiedWhy we changed it
Registry
Glioma — the first condition term the registry derived for this study.
ClinicalTrials.gg
Glioblastoma
Why
  1. The study's listed conditions name Glioblastoma, a narrower term within Glioma.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Sichuan Luzhou Buchang Biopharmaceutical Co., Ltd. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jun 2026, 5 months ago, but the record still lists the study as recruiting.
  • Started Apr 2025; still recruiting 1 year 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 142 studies in Glioblastoma with a site in China — 73 open to participants now, 80 under way, 7 of them phase 3. Glioblastoma · China.

Planned enrollment
52nd of 127
40 · median 36
Started
2025
with 15 others
Phase 1
45 of 142
22 open now
Primary completion
2026-06
later than 30 of 79 live
Registered
102nd of 142
by date

Among the 142 studies in Glioblastoma with a site in China, this one is the 52nd largest by planned enrollment of the 127 interventional ones that give a count, is one of 16 that started in 2025, is one of 45 in phase 1, reaches primary completion later than 30 of the 79 other live ones, and was the 102nd registered.

Glioblastoma

2,135 studies on the registry are indexed under Glioblastoma; 465 are open to participants now.

Browse Glioblastoma studies →

Open to participants now

73 of the 142 studies in Glioblastoma with a site in China are open now. Recruiting first, the newest first:

68 more — sign in →

All 73 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 338 Glioblastoma studies recruiting now, 233 (69%) set no upper age limit and 65 (19%) stop at 75 or younger; 27 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 142 studies in Glioblastoma with a site in China, or all of them as a file.
02

Study summary

The purpose of this Phase I clinical study is to evaluate the safety, preliminary efficacy and pharmacokinetic characteristics of BC008-1A injection in subjects with recurrent CNS WHO grade 4 glioma. This is a randomized and open-label study, with two dose groups set up, and 10 to 20 subjects will be enrolled in each group.

Read the detailed description

BC008-1A is an innovative bispecific antibody targeting TIGIT and PD-1, which is developed by Sichuan Luzhou Buchang Biopharmaceutical Co., Ltd. . BC008-1A targets PD-1 and TIGIT to block the relevant signaling pathways, relieve the inhibition on T lymphocytes, thereby facilitating the activation of T cells and achieving the functions of immune surveillance, recognition and killing of tumor cells. Subjects with recurrent CNS WHO grade 4 glioma will be randomly assigned to dose group A (900 mg) or B (1200 mg) at a ratio of 1:1. BC008-1A will be administered once every 3 weeks until disease progression, intolerable toxicity, withdrawal of informed consent, loss to follow-up, initiation of new anti-tumor treatment, the decision of the investigator for the subject to withdraw based on the subject's benefit situation, death or other circumstances, whichever occurs first.

03

Conditions studied

  • Glioma
  • Glioma Tumor Recurrence
  • Glioma, Recurrent High Grade
  • Glioblastomas (GBM)
  • Glioblastoma WHO Grade IV

Browse trials for

Keywords

  • glioma
  • PD-1
  • TIGIT
  • bispecific antibody
  • glioblastoma
04

In context

Glioblastoma Reclassified

2,135 studies on the registry are indexed under Glioblastoma; 465 are open to participants now.

This study's planned enrollment of 40 is above the median of 36 across 1,756 interventional studies indexed under Glioblastoma.

Browse Glioblastoma studies →

Lead sponsor

Sichuan Luzhou Buchang Biopharmaceutical Co., Ltd. is the lead sponsor of 3 studies on the registry; 3 are open to participants now.

Compared within Glioblastoma, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Glioma. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Voluntarily sign the form;
  2. Recurrent CNS WHO grade 4 glioma: Subjects with CNS WHO grade 4 glioma confirmed by histopathology, who have experienced disease progression as diagnosed by MRI and evaluated by RANO criteria after standard treatment and have no surgical plan;
  3. Male or female aged ≥ 18 years old;
  4. Expected survival time ≥ 12 weeks;
  5. According to the RANO criteria, there is at least one measurable intracranial tumor lesion;
  6. ≥ 70;
  7. Have sufficient hematological function, liver function and renal function, and meet the following laboratory test results before enrollment (withoutusing any cell growth factors, and red blood cell transfusion or other blood transfusion treatments within 1 week before the first dose of study treatment):

    • Basically normal liver function: Total (TBIL) ≤ 1.5 × (patients with known Gilbert disease with serum bilirubin level ≤3 × ULN can be included), (ALT) ≤ 2.5 × ULN, aspartate aminotransferase (AST) ≤ 2.5 × ULN, alkaline phosphatase ≤ 2.5 × ULN;
    • Basically normal renal function: Creatinine (Cr) ≤ 1.5 × ULN, or estimated (eGFR) ≥ 30 mL/min;
    • Basically normal coagulation function: (INR) ≤ 1.5 × ULN, prothrombin time (PT) ≤ 1.5 × ULN, activated partial thromboplastin time (APTT) ≤ 1.5 × ULN (for subjects receiving anticoagulant treatment, the investigator judges that INR, PT and APTT are within the safe and effective treatment range and there is no clinical condition of active bleeding or increased bleeding risk);
    • Basically normal hematological system: (ANC) ≥ 1.5 × 10\^9/L (without granulocyte colony-stimulating factor treatment), platelet (PLT) ≥ 100 × 10\^9/L, (Hb) ≥ 90 g/L, white blood cell count ≥ 2.0 × 10\^9/L, lymphocyte count ≥ 0.5 ×10\^9/L.
  8. Female subjects of childbearing age or male subjects whose partners are women of childbearing age need to agree to take effective measures during the trial period (from signing the ICF to 6 months after the last dose).

Exclusion criteria

Exclusion Criteria:

  1. Having been previously exposed to any anti-TIGIT, , PD-L1 or CTLA-4 drugs;
  2. Having suffered from other malignant tumors and currently requiring treatment (except for cervical carcinoma in situ, basal cell carcinoma or squamous cell carcinoma of the skin that have been adequately treated);
  3. Having an disease or a history of autoimmune diseases or related symptoms;
  4. Subjects who cannot undergo MRI (such as those with a pacemaker implanted, non-removable metal dentures, claustrophobia, etc.);
  5. Subjects who have received chemotherapy (those who have used nitrosourea drugs within 42 days before the first receipt of the experimental drug cannot be enrolled), radiotherapy, biotherapy, endocrine therapy, targeted therapy, tumor-treating fields therapy, immunotherapy or other anti-tumor treatments such as anti-tumor Chinese patent medicines within 28 days before the first use of the study drug or within 5 half-lives of the drug (whichever is shorter), or subjects who have received any clinical study treatment and the interval from the first use of the study drug is ≤ 28 days;
  6. Subjects with tumor lesions involving the brainstem, spinal cord or dissemination and ;
  7. Those who have used within 1 month before participating in the trial and have received systemic treatment with a daily dose higher than 3 mg of dexamethasone or an equivalent dose of other hormones;
  8. The toxicity caused by previous anti-tumor treatments has not decreased to ≤ grade 1 as defined in version 5.0 (except for toxicities judged by the investigator to have no safety risks, such as alopecia, grade 2 peripheral neurotoxicity, hypothyroidism stabilized by hormone replacement therapy, etc.);
  9. Those who have received within 4 weeks before the first administration of the study drug or plan to receive them during the study period;
  10. Subjects with active infections at present (such as acute bacterial infections, tuberculosis, pulmonary infections, etc.);
  11. Those who are positive for core antibody (HBcAb) or hepatitis B surface antigen (HBsAg), and whose HBV DNA is higher than the value of the site, or those judged by doctors to have active hepatitis, virus (HCV) infection, or those who are positive for (HIV) antibody, or those who are positive for Treponema pallidum antibody (Tp-Ab);
  12. Those with cardiac clinical symptoms or diseases that are not well controlled, such as uncontrolled hypertension (systolic blood pressure ≥ 160 mmHg and/or diastolic blood pressure ≥ 100 mmHg), unstable angina pectoris or myocardial infarction occurring within 6 months before enrollment in the trial, or poorly controlled arrhythmias (including ≥ 450 ms for men and ≥ 470 ms for women, with the QTc interval calculated by the Fridericia formula), etc.;
  13. Cardiac function classified as grade III or IV according to the (NYHA) classification;
  14. Those who are allergic to the components or of the experimental drug, antibody drugs or any other therapeutic proteins (such as fresh frozen plasma, human serum albumin, cytokines or interleukins, etc.), or those with a history of severe allergies and suspected to have severe allergic reactions (NCI-CTCAEv5.0 ≥ grade 3);
  15. Those with a clear history of neurological or mental disorders in the past, such as dementia, and with poor compliance;
  16. Those with epilepsy and/or increased intracranial pressure that are difficult to control by drugs;
  17. Pregnant or lactating women;
  18. Other situations that the investigator deems unsuitable for participating in this study.
Terms in these criteria, in plain language(24)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

06

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    BC008-1A 900mg

    Biological: BC008-1A

  • Experimental
    BC008-1A 1200mg

    Biological: BC008-1A

Interventions

  • BiologicalBC008-1A

    Biological: 900 mg BC008-1A will be intravenously injected once every 3 weeks.

  • BiologicalBC008-1A

    Biological: 1200 mg BC008-1A will be intravenously injected once every 3 weeks.

07

What researchers measure

Primary outcomes

  1. Safety

    Assesing the type, frequency, severity, and duration of adverse events.

    Time frame: Up to 2 years

Secondary outcomes

  1. objective response rate (ORR)

    Defined as the proportion of patients who have a complete response (CR) or a partial response (PR) per RANO.

    Time frame: Up to 2 years

  2. Maximum Plasma Concentration (Cmax)

    Time frame: 3 months

  3. Immunogenicity

    The number and incidence of subjects with anti-drug antibodies (ADA).

    Time frame: Up to 2 years

  4. Karnofsky performance score(KPS)

    To evaluate the change of KPS from baseline.

    Time frame: Up to 2 years

  5. Recommended phase II dose

    To determine the recommended dose for the Phase II clinical study based on the results of safety, preliminary efficacy and pharmacokinetics

    Time frame: Up to 2 years

  6. Progression-free survival(PFS)

    The time interval from the first drug administration to progression per RANO or death from any cause

    Time frame: Up to 2 years

  7. Overall survival (OS)

    The time interval from the first drug administration to death due to any cause.

    Time frame: Up to 2 years

  8. Duration of overall response (DoR)

    the time interval from the first discovery of response (CR or PR) to progression per RANO or death from any cause

    Time frame: Up to 2 years

  9. Disease control rate (DCR)

    Defined as the proportion of subjects who achieved a best response of Complete Response (CR), Partial Response (PR), or Stable Disease (SD) per RANO.

    Time frame: Up to 2 years

  10. Time to response (TTR)

    The time from the first drug administration to the first confirmation of Complete Response (CR) or Partial Response (PR) per RANO.

    Time frame: Up to 2 years

  11. Area under the curve (AUC)

    Time frame: 3 months

08

Study locations

1 of 1 sites recruiting
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2025 (actual). Primary completion is estimated for Jun 2026, 14 months after the start.

Of 82 industry-sponsored phase 1 interventional studies under Glioblastoma, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 64. This study's planned 14 months is below that.

Counting every sponsor, half of 321 studies reached it within 44 months; a quarter within 29 and three quarters within 73.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 2, 2025
First posted
Jan 14, 2025
StartActual
Apr 7, 2025
Primary completionEst.
Jun 2026
CompletionEst.
Dec 2026
Last update
Jul 9, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 9, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06773481
Lead sponsor
Sichuan Luzhou Buchang Biopharmaceutical Co., Ltd.
Responsible party
Sponsor
First posted
Jan 14, 2025
Start date
Apr 7, 2025
Primary completion
Jun 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Jul 9, 2025

Study contacts

Jianing Wang
Contact
wangjianing@buchangbio.com
86-13802107048
Xinlei Guo
Contact
guoxinlei@buchangbio.com
0086-10-87163362

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion